Pulmonary complications have been reported in approximately 35% of patients undergoing dasatinib therapy. Dasatinib, a second-generation BCR-ABL tyrosine kinase inhibitor, is often the preferred therapy for individuals undergoing treatment for Philadelphia-positive CML. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.